Date: 2017-01-08
Type of information: Development agreement
Compound: NGS-based clonoSEQ Assay
Company: Amgen (USA - CA) Adaptive Biotechnologies (USA - WA)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: development commercialisation
Action mechanism: diagnostic test. The Adaptive Biotechnologies clonoSEQ Assay enables physicians to utilize next-generation sequencing-based minimal/measureable residual disease (MRD) detection to inform clinical decision making for patients with lymphoid malignancies. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which allows physicians to visualize response to treatment over time to optimize patient management.
Disease: acute lymphoblastic leukemia (ALL)
Details: * On January 6, 2017, Adaptive Biotechnologies, a leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced it has entered into an agreement with Amgen to further develop and commercialize Adaptive’s NGS-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL). Through the collaboration, the parties will work towards building the dataset for MRD as a validated measure of patient outcomes in ALL. Adaptive will be seeking marketing authorization from FDA for the clonoSEQ Assay.
Financial terms:
Latest news:
